Abstract
Objective. To assess the utility of dose frequency adjustment of tocilizumab (TCZ) in rheumatoid arthritis (RA). Methods. Patients who received TCZ at 3-week (n = 24) or 5-week (n = 61) interval were evaluated. Results. Disease Activity Score at 28 joints based on erythrocyte sedimentation rate in the 3-week group significantly improved after 3 administrations at 3-week intervals (from 4.2 to 2.7, p = 0.001). Forty-five of the patients in the 5-week group (74%) successfully continued 5-week interval administration without disease exacerbation. Lower C-reactive protein level at TCZ initiation and shorter duration to remission achievement were key to successful dose frequency reduction. Conclusion. Adjusting the dose frequency of intravenous TCZ is a useful strategy.
| Original language | English |
|---|---|
| Pages (from-to) | 553-557 |
| Number of pages | 5 |
| Journal | Journal of Rheumatology |
| Volume | 44 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2017 May 1 |
Fingerprint
Keywords
- Arthritis
- Rheumatoid
- Tocilizumab
ASJC Scopus subject areas
- Immunology and Allergy
- Rheumatology
- Immunology
Cite this
Utility of dose frequency adjustment in tocilizumab administration for rheumatoid arthritis. / Saito, Shuntaro; Kaneko, Yuko; Izumi, Keisuke; Takeuchi, Tsutomu.
In: Journal of Rheumatology, Vol. 44, No. 5, 01.05.2017, p. 553-557.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Utility of dose frequency adjustment in tocilizumab administration for rheumatoid arthritis
AU - Saito, Shuntaro
AU - Kaneko, Yuko
AU - Izumi, Keisuke
AU - Takeuchi, Tsutomu
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Objective. To assess the utility of dose frequency adjustment of tocilizumab (TCZ) in rheumatoid arthritis (RA). Methods. Patients who received TCZ at 3-week (n = 24) or 5-week (n = 61) interval were evaluated. Results. Disease Activity Score at 28 joints based on erythrocyte sedimentation rate in the 3-week group significantly improved after 3 administrations at 3-week intervals (from 4.2 to 2.7, p = 0.001). Forty-five of the patients in the 5-week group (74%) successfully continued 5-week interval administration without disease exacerbation. Lower C-reactive protein level at TCZ initiation and shorter duration to remission achievement were key to successful dose frequency reduction. Conclusion. Adjusting the dose frequency of intravenous TCZ is a useful strategy.
AB - Objective. To assess the utility of dose frequency adjustment of tocilizumab (TCZ) in rheumatoid arthritis (RA). Methods. Patients who received TCZ at 3-week (n = 24) or 5-week (n = 61) interval were evaluated. Results. Disease Activity Score at 28 joints based on erythrocyte sedimentation rate in the 3-week group significantly improved after 3 administrations at 3-week intervals (from 4.2 to 2.7, p = 0.001). Forty-five of the patients in the 5-week group (74%) successfully continued 5-week interval administration without disease exacerbation. Lower C-reactive protein level at TCZ initiation and shorter duration to remission achievement were key to successful dose frequency reduction. Conclusion. Adjusting the dose frequency of intravenous TCZ is a useful strategy.
KW - Arthritis
KW - Rheumatoid
KW - Tocilizumab
UR - http://www.scopus.com/inward/record.url?scp=85018287459&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018287459&partnerID=8YFLogxK
U2 - 10.3899/jrheum.161047
DO - 10.3899/jrheum.161047
M3 - Article
C2 - 28298563
AN - SCOPUS:85018287459
VL - 44
SP - 553
EP - 557
JO - Journal of Rheumatology
JF - Journal of Rheumatology
SN - 0315-162X
IS - 5
ER -